People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rivus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $223.5M | $416.3M | 2025 |
Tom O'Neil at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tom O'Neil on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Enright | 1 | 10 |
| Derek DiRocco | 1 | 7 |
| Ian Smith | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Erin Lavelle | 1 | 3 |
| Jayson Dallas | 1 | 2 |
| Nancy Hargreaves | 1 | 2 |
| Robert Schott | 1 | 1 |
| Shaharyar Khan | 1 | 1 |
| Rick Winningham | 1 | 1 |
| Allen Cunningham | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.